Identification of cuproptosis-related diagnostic biomarkers in idiopathic pulmonary fibrosis

Qi Wang,Yu Shang,Yupeng Li,Xincheng Li,Xue Wang,Yaowu He,Jing Ma,Shangwei Ning,Hong Chen
DOI: https://doi.org/10.1097/md.0000000000036801
IF: 1.6
2024-01-13
Medicine
Abstract:Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, and fibrotic interstitial lung disease, has a persistent decline in lung function and progressive worsening of symptoms. [ 1 , 2 ] IPF patients have a poor prognosis, with a median survival of 3 to 5 years. [ 3 ] Currently, the only approach to IPF is lung transplantation, and pirfenidone and nintedanib can only delay the progression of the disease. [ 4 ] Therefore, there is an urgent need to explore valid new diagnostic biomarkers and therapeutic targets for IPF in order to save more patients' lives.
medicine, general & internal
What problem does this paper attempt to address?